Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Mcgregor (2008)
Discovering and improving novel peptide therapeutics.Current opinion in pharmacology, 8 5
B. Mossman, A. Churg (1998)
Mechanisms in the pathogenesis of asbestosis and silicosis.American journal of respiratory and critical care medicine, 157 5 Pt 1
B. Tomasini-Johansson, Nicole Kaufman, Martin Ensenberger, V. Ozeri, E. Hanski, D. Mosher (2001)
A 49-Residue Peptide from Adhesin F1 of Streptococcus pyogenes Inhibits Fibronectin Matrix Assembly*The Journal of Biological Chemistry, 276
P. Bailon, A. Palleroni, Carol Schaffer, C. Spence, Wen-Jian Fung, J. Porter, G. Ehrlich, Wenkai Pan, Zhi-xin Xu, M. Modi, and Farid, W. Berthold, M. Graves (2001)
Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.Bioconjugate chemistry, 12 2
P. Guerra, C. Acklin, A. Kosky, Janice Davis, M. Treuheit, D. Brems (1998)
PEGylation Prevents the N-Terminal Degradation of Megakaryocyte Growth and Development FactorPharmaceutical Research, 15
P. McKeown-Longo, D. Mosher (1985)
Interaction of the 70,000-mol-wt amino-terminal fragment of fibronectin with the matrix-assembly receptor of fibroblastsThe Journal of Cell Biology, 100
L. Maurer, Wenjian Ma, D. Mosher (2016)
Dynamic structure of plasma fibronectinCritical Reviews in Biochemistry and Molecular Biology, 51
J. Schwarzbauer (1991)
Identification of the fibronectin sequences required for assembly of a fibrillar matrixThe Journal of Cell Biology, 113
C. Moore, Xiu‐da Shen, F. Gao, R. Busuttil, A. Coito (2007)
Fibronectin-4 1 Integrin Interactions Regulate Metalloproteinase-9 Expression in Steatotic Liver Ischemia and Reperfusion Injury
O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, C. Gegg (2002)
Mono-N-terminal poly(ethylene glycol)-protein conjugates.Advanced drug delivery reviews, 54 4
M. Filla, Kaylee Dimeo, Tie-gang Tong, D. Peters (2017)
Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cellsExperimental Eye Research, 165
J. Sottile, D. Hocking (2002)
Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions.Molecular biology of the cell, 13 10
T. Cox, D. Bird, A. Baker, H. Barker, M. Ho, G. Lang, J. Erler (2013)
LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis.Cancer research, 73 6
D. Rudmann, J. Alston, J. Hanson, S. Heidel (2013)
High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to ProteinsToxicologic Pathology, 41
G. Pasut, F. Veronese (2012)
State of the art in PEGylation: the great versatility achieved after forty years of research.Journal of controlled release : official journal of the Controlled Release Society, 161 2
Lisa Tang, A. Persky, G. Hochhaus, B. Meibohm (2004)
Pharmacokinetic aspects of biotechnology products.Journal of pharmaceutical sciences, 93 9
H. Kenny, Chun-Yi Chiang, Erin White, E. Schryver, M. Habis, Iris Romero, A. Ladányi, Carla Penicka, J. George, K. Matlin, A. Montag, K. Wroblewski, S. Yamada, A. Mazar, D. Bowtell, E. Lengyel (2014)
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.The Journal of clinical investigation, 124 10
B. Tomasini-Johansson, Ian Johnson, F. Hoffmann, Deane Mosher (2012)
Quantitative microtiter fibronectin fibrillogenesis assay: use in high throughput screening for identification of inhibitor compounds.Matrix biology : journal of the International Society for Matrix Biology, 31 6
J. Harris, Robert Chess (2003)
Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2
M. Coughlin (2000)
Radial Scars in Benign Breast‐Biopsy Specimens and the Risk of Breast CancerAORN Journal, 71
C. Fishburn (2008)
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.Journal of pharmaceutical sciences, 97 10
T. Yamaoka, Y. Tabata, Y. Ikada (1994)
Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice.Journal of pharmaceutical sciences, 83 4
OB Kinstler, DN Brems, SL Lauren, AG Paige, JB Hamburger, TMJ Characterization (1996)
Stability of N-terminally PEGylated rhG-CSFPharm Res, 13
Wenjun Li, P. Zhan, E. Clercq, H. Lou, Xinyong Liu (2013)
Current drug research on PEGylation with small molecular agentsProgress in Polymer Science, 38
Anil Tiwari, R. Kumar, J. Ram, Maryada Sharma, M. Luthra-Guptasarma (2016)
Control of fibrotic changes through the synergistic effects of anti-fibronectin antibody and an RGDS-tagged form of the same antibodyScientific Reports, 6
E. Altrock, Carla Sens, Carina Wuerfel, M. Vasel, N. Kawelke, S. Dooley, J. Sottile, I. Nakchbandi (2014)
Inhibition of fibronectin deposition improves experimental liver fibrosis.Journal of hepatology, 62 3
Purva Singh, C. Carraher, J. Schwarzbauer (2010)
Assembly of fibronectin extracellular matrix.Annual review of cell and developmental biology, 26
Richard Ross, Kin Leung, M. Maamra, W. Bennett, N. Doyle, Michael Waters, Ken Ho (2001)
Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.The Journal of clinical endocrinology and metabolism, 86 4
J. Ehling, J. Bábíčková, F. Gremse, B. Klinkhammer, Sarah Baetke, R. Knuechel, F. Kiessling, J. Floege, T. Lammers, P. Boor (2016)
Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases.Journal of the American Society of Nephrology : JASN, 27 2
Matthew Weinstock, J. Francis, Joseph Redman, M. Kay (2012)
Protease‐resistant peptide design—empowering nature's fragile warriors against HIVPeptide Science, 98
L. Maurer, B. Tomasini-Johansson, Wenjian Ma, D. Annis, Nathan Eickstaedt, Martin Ensenberger, K. Satyshur, D. Mosher (2010)
Extended Binding Site on Fibronectin for the Functional Upstream Domain of Protein F1 of Streptococcus pyogenes*The Journal of Biological Chemistry, 285
Sang-Heon Lee, Seulki Lee, Y. Youn, D. Na, S. Chae, Y. Byun, Kang-Choon Lee (2005)
Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.Bioconjugate chemistry, 16 2
J. Bábíčková, B. Klinkhammer, E. Buhl, S. Djudjaj, M. Hoss, F. Heymann, F. Tacke, J. Floege, J. Becker, P. Boor (2017)
Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries.Kidney international, 91 1
S. Dallas, P. Sivakumar, Carolyn Jones, Qian Chen, D. Peters, D. Mosher, M. Humphries, C. Kielty (2005)
Fibronectin Regulates Latent Transforming Growth Factor-β (TGFβ) by Controlling Matrix Assembly of Latent TGFβ-binding Protein-1*Journal of Biological Chemistry, 280
O. Kinstler, D. Brems, S. Lauren, Amiee Paige, James Hamburger, M. Treuheit (1996)
Characterization and Stability of N-terminally PEGylated rhG-CSFPharmaceutical Research, 13
Yu‐Sen Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, D. Wyss (2002)
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.Advanced drug delivery reviews, 54 4
Pharm Res (2018) 35: 126 https://doi.org/10.1007/s11095-018-2412-7 RESEARCH PAPER Characterization of the PEGylated Functional Upstream Domain Peptide (PEG-FUD): a Potent Fibronectin Assembly Inhibitor with Potential as an Anti-Fibrotic Therapeutic 1 1 2 1 Pawel Zbyszynski & Bianca R. Tomasini-Johansson & Donna M. Peters & Glen S. Kwon Received: 17 March 2018 /Accepted: 17 April 2018 /Published online: 24 April 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 ABSTRACT that PEG-FUD holds promise as an effective anti-fibrotic with Purpose To develop PEGylated variants of pUR4/FUD therapeutic potential and a candidate for further pharmaco- (FUD), a fibronectin assembly inhibitor, using 10 kDa, kinetic and biodistribution studies. 20 kDa, and 40 kDa PEGs to evaluate their binding affinity and inhibitory potency. . . . KEYWORDS Anti-fibrosis therapy fibronectin PEG Methods The FUD peptide was recombinantly expressed, peptide delivery pUR4/FUD purified, and PEGylated at the N-terminus using 10 kDa, 20 kDa, and 40 kDa methoxy-PEG aldehyde. The PEGylates were purified and fractionated using ion- ABBREVIATIONS exchange chromatography. The molecular weight and degree 70 K 70 kDa N-terminal region of fibronectin of PEGylation of each conjugate was verified using MALDI- ECM Extracellular Matrix TOF. The binding affinity of each PEG-FUD conjugate was
Pharmaceutical Research – Springer Journals
Published: Apr 24, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.